1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,970 | 2,990 | 08:42 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Biohit Oyj: Biohit Group Half Year Financial Report 2025 (unaudited) | 132 | GlobeNewswire (Europe) | BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2025 (unaudited)
Biohit Oyj Half Year Financial Report 6 August 2025 at 9:30 am local time (EET)
SUMMARY
January-June 2025
Revenue EUR 7.4 million (EUR 7.4... ► Artikel lesen | |
| 04.06. | Biohit Oyj: Decisions of the Annual General Meeting of Biohit Oyj | 116 | GlobeNewswire (Europe) | Decisions of the Annual General Meeting of Biohit Oyj
Biohit Oyj Decisions of the Annual General Meeting, June 4, 2025 at 6.00 pm local time (EET)
The Annual General Meeting (AGM) of Biohit Oyj held... ► Artikel lesen | |
| 12.02. | Biohit Oyj: Biohit Group Financial Statement Release 2024 | 107 | GlobeNewswire (Europe) | BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2024
Biohit Oyj Financial Statement Release 12 February 2025 at 9:30 am local time (EET)
SUMMARY
January-December 2024
Revenue EUR 14.3 million (EUR 13.1... ► Artikel lesen | |
| 16.01. | Biohit Oyj: BIOHIT secures European distribution rights for Biomedal's gluten immunogenic peptide tests | 205 | GlobeNewswire (Europe) | BIOHIT secures European distribution rights for Biomedal's gluten immunogenic peptide tests
Biohit Oyj Press release 16 January 2025 at 11.00 am local time (EEST)
BIOHIT is excited to announce an agreement... ► Artikel lesen | |
| 08.01. | Biohit Oyj: Approval of Biohit's GastroPanel test for use by the British National Health Service (NHS) takes a major step forward | 348 | GlobeNewswire (Europe) | Approval of Biohit's GastroPanel® test for use by the British National Health Service (NHS) takes a major step forward
Biohit Oyj Press release 8 January 2025 at 10.30 am local time (EEST)
A study... ► Artikel lesen | |
| BIOHIT Aktie jetzt für 0€ handeln | |||||
| 19.12.24 | Biohit Oyj: Insider information, profit warning: Biohit lowers its guidance for 2024 | 211 | GlobeNewswire (Europe) | Insider information, profit warning: Biohit lowers its guidance for 2024
Biohit Oyj, Stock Exchange Release December 19th, 2024, at 11:00 am (EET)Biohit is lowering its guidance for 2024 revenue. Sales... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,675 | +0,53 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,50 | +2,39 % | Tarsus outlines $140M-$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress | ||
| HARMONY BIOSCIENCES | 30,720 | 0,00 % | Harmony Biosciences raises 2025 revenue outlook to $845M-$865M amid record WAKIX patient growth and advancing pipeline | ||
| AVIDITY BIOSCIENCES | 69,83 | +0,06 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| EVOTEC | 7,086 | +1,14 % | Millionen für BioNTech und Evotec! Doch Medikamentenentwicklung kostet! Deshalb auf den Übernahmekandidaten NetraMark Aktie setzen!? | Nächste Erfolgsmeldung für NetraMark. Die KI des Unternehmens hat das nächste Biopharmaunternehmen überzeugt und wird immer mehr zum Übernahmekandidaten. Der neue Kunde will mit NetraAI seine klinische... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 17,325 | -3,59 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,000 | 0,00 % | Recursion Pharmaceuticals Q3 2025 Earnings Preview | ||
| PRAXIS PRECISION MEDICINES | 171,86 | -5,57 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| MODERNA | 21,330 | -2,71 % | Moderna: Neues zur Tumor-Therapie mRNA-2808 | Moderna hat den ersten Patient in einer klinischen Phase-1/2-Studie mit dem Wirkstoffkandidaten mRNA-2808 behandelt. Der mRNA-basierte T-Cell-Engager wird nach Angaben des US-Biotechunternehmens vom... ► Artikel lesen | |
| UPSTREAM BIO | 25,040 | +0,08 % | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,140 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug... ► Artikel lesen | |
| PRIME MEDICINE | 4,300 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer | CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,620 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,495 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,710 | 0,00 % | Beam Therapeutics GAAP EPS of -$1.10 misses by $0.09, revenue of $9.69M misses by $3.03M |
BIOHIT OYJ gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,980 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOHIT OYJ finden Sie auf Wallstreet Online.